Recombinant vaccinia virus and methods of use thereof
AssigneeIgnite Immunotherapy, Inc.
InventorsDouglas Hanahan, David H. Kirn, Liliana Maruri Avidal, Michael D. Eisenbraun, Joseph J. Binder, Clare Lees
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus. The present disclosure also provides use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
Claims9
A replication-competent, recombinant oncolytic vaccinia virus comprising, in its genome, a nucleotide sequence encoding a variant interleukin 2 (IL-2v) polypeptide comprising the amino acid sequence of SEQ ID NO:9, wherein the nucleotide sequence encoding the variant IL-2v polypeptide comprises the nucleotide sequence of SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12.
Dependencies are inferred from the claim text.